Clinical Trial Update: Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a personalized neoantigen vaccine in combination with locally administered ipilimumab and systemic nivolumab for advanced melanoma. Res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Neoantigen vaccine
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Cutaneous Melanoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-31